Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Biosimilar Insulin industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
Eli Lilly and Company
Aspen
Sanofi
BGP Pharma
Mylan (Viatris)
By Type:
Others
Insulin Glargine
Insulin Analog
By Application:
Hospital Pharmacies
Others
Retail Pharmacies
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Biosimilar Insulin Market Overview 2018-2029
-
1.1 China Biosimilar Insulin Industry Development Overview
-
1.2 China Biosimilar Insulin Industry Development History
-
1.3 China Biosimilar Insulin Industry Market Size (2018-2029)
-
1.4 China Biosimilar Insulin Market Analysis by Type from Production Side
-
1.4.1 China Biosimilar Insulin Production Volume, Production Value and Growth Rate of Others (2018-2029)
-
1.4.2 China Biosimilar Insulin Production Volume, Production Value and Growth Rate of Insulin Glargine (2018-2029)
-
1.4.3 China Biosimilar Insulin Production Volume, Production Value and Growth Rate of Insulin Analog (2018-2029)
-
1.5 China Biosimilar Insulin Market Analysis by Application from Consumption End
-
1.5.1 China Biosimilar Insulin Sales Volume, Sales Value and Growth Rate of Hospital Pharmacies (2018-2029)
-
1.5.2 China Biosimilar Insulin Sales Volume, Sales Value and Growth Rate of Others (2018-2029)
-
1.5.3 China Biosimilar Insulin Sales Volume, Sales Value and Growth Rate of Retail Pharmacies (2018-2029)
-
1.6 China Biosimilar Insulin Market Analysis by Region
-
1.6.1 North China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
Chapter 2 China Biosimilar Insulin Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Biosimilar Insulin Market Status and Competition at home and abroad in 2023
-
2.2.2 China Biosimilar Insulin Market Status and Competition Analysis in 2023
-
2.2.3 China Biosimilar Insulin Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Biosimilar Insulin Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Biosimilar Insulin Industry Development
Chapter 3 Biosimilar InsulinIndustry Chain Analysis
-
3.1 Biosimilar Insulin Industry Chain
-
3.2 Biosimilar Insulin Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Biosimilar Insulin Market
-
3.3 Biosimilar Insulin Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Biosimilar Insulin Market
Chapter 4 China Biosimilar Insulin Market, by Type
-
4.1 China Biosimilar Insulin Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Biosimilar Insulin Total Production Volume and Growth Rate from Production Side
-
4.5 China Biosimilar Insulin Production Volume and Growth Rate, by Type
-
4.5.1 China Biosimilar Insulin Production Volume and Growth Rate of Others
-
4.5.2 China Biosimilar Insulin Production Volume and Growth Rate of Insulin Glargine
-
4.5.3 China Biosimilar Insulin Production Volume and Growth Rate of Insulin Analog
Chapter 5 China Biosimilar Insulin Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Biosimilar Insulin Total Market Size and Growth Rate from Consumption End
-
5.5 China Biosimilar Insulin Market Size and Growth Rate, by Application
-
5.5.1 China Biosimilar Insulin Market Size and Growth Rate of Hospital Pharmacies
-
5.5.2 China Biosimilar Insulin Market Size and Growth Rate of Others
-
5.5.3 China Biosimilar Insulin Market Size and Growth Rate of Retail Pharmacies
Chapter 6 China Biosimilar Insulin Market, by Region
-
6.1 China Biosimilar Insulin Production Volume and Production Value, by Region
-
6.2 China Biosimilar Insulin Sales Volume and Sales Value, by Region
Chapter 7 North China Biosimilar Insulin Market Analysis
-
7.1 North China Biosimilar Insulin Market, by Type
-
7.2 North China Biosimilar Insulin Market, by Application
Chapter 8 Central China Biosimilar Insulin Market Analysis
-
8.1 Central China Biosimilar Insulin Market, by Type
-
8.2 Central China Biosimilar Insulin Market, by Application
Chapter 9 South China Biosimilar Insulin Market Analysis
-
9.1 South China Biosimilar Insulin Market, by Type
-
9.2 South China Biosimilar Insulin Market, by Application
Chapter 10 East China Biosimilar Insulin Market Analysis
-
10.1 East China Biosimilar Insulin Market, by Type
-
10.2 East China Biosimilar Insulin Market, by Application
Chapter 11 Northeast China Biosimilar Insulin Market Analysis
-
11.1 Northeast China Biosimilar Insulin Market, by Type
-
11.2 Northeast China Biosimilar Insulin Market, by Application
Chapter 12 Southwest China Biosimilar Insulin Market Analysis
-
12.1 Southwest China Biosimilar Insulin Market, by Type
-
12.2 Southwest China Biosimilar Insulin Market, by Application
Chapter 13 Northwest China Biosimilar Insulin Market Analysis
-
13.1 Northwest China Biosimilar Insulin Market, by Type
-
13.2 Northwest China Biosimilar Insulin Market, by Application
Chapter 14 Company Profiles
-
14.1 Eli Lilly and Company
-
14.1.1 Eli Lilly and Company Company Profile
-
14.1.2 Eli Lilly and Company Biosimilar Insulin Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Aspen
-
14.2.1 Aspen Company Profile
-
14.2.2 Aspen Biosimilar Insulin Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Sanofi
-
14.3.1 Sanofi Company Profile
-
14.3.2 Sanofi Biosimilar Insulin Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 BGP Pharma
-
14.4.1 BGP Pharma Company Profile
-
14.4.2 BGP Pharma Biosimilar Insulin Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Mylan (Viatris)
-
14.5.1 Mylan (Viatris) Company Profile
-
14.5.2 Mylan (Viatris) Biosimilar Insulin Market Performance
-
14.5.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Biosimilar Insulin Industry Research Conclusions
-
15.2 Biosimilar Insulin Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Biosimilar Insulin Industry Market Size (2018-2029)
-
Figure China Biosimilar Insulin Production Volume, Production Value and Growth Rate of Others (2018-2029)
-
Figure China Biosimilar Insulin Production Volume, Production Value and Growth Rate of Insulin Glargine (2018-2029)
-
Figure China Biosimilar Insulin Production Volume, Production Value and Growth Rate of Insulin Analog (2018-2029)
-
Figure China Biosimilar Insulin Sales Volume, Sales Value and Growth Rate of Hospital Pharmacies (2018-2029)
-
Figure China Biosimilar Insulin Sales Volume, Sales Value and Growth Rate of Others (2018-2029)
-
Figure China Biosimilar Insulin Sales Volume, Sales Value and Growth Rate of Retail Pharmacies (2018-2029)
-
Figure North China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
Figure Central China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
Figure South China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
Figure East China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Biosimilar Insulin Market Size and Growth Rate from 2018-2029
-
Figure Biosimilar Insulin Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Biosimilar Insulin Market Share by Type in 2018
-
Figure China Biosimilar Insulin Market Share by Type in 2023
-
Figure China Biosimilar Insulin Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Biosimilar Insulin Production Volume and Growth Rate of Others (2018-2023)
-
Figure China Biosimilar Insulin Production Volume and Growth Rate of Insulin Glargine (2018-2023)
-
Figure China Biosimilar Insulin Production Volume and Growth Rate of Insulin Analog (2018-2023)
-
Figure China Biosimilar Insulin Market Share by Application in 2018
-
Figure China Biosimilar Insulin Market Share by Application in 2023
-
Figure China Biosimilar Insulin Total Market Size and Growth Rate from Consumption End
-
Figure China Biosimilar Insulin Market Size and Growth Rate of Hospital Pharmacies (2018-2023)
-
Figure China Biosimilar Insulin Market Size and Growth Rate of Others (2018-2023)
-
Figure China Biosimilar Insulin Market Size and Growth Rate of Retail Pharmacies (2018-2023)
-
Table China Biosimilar Insulin Production Volume by Region (2018-2023)
-
Table China Biosimilar Insulin Production Volume Share by Region (2018-2023)
-
Figure China Biosimilar Insulin Production Volume Share by Region (2018-2023)
-
Table China Biosimilar Insulin Production Value by Region (2018-2023)
-
Table China Biosimilar Insulin Production Value Share by Region (2018-2023)
-
Figure China Biosimilar Insulin Production Value Share by Region (2018-2023)
-
Table China Biosimilar Insulin Sales Volume by Region (2018-2023)
-
Table China Biosimilar Insulin Sales Volume Share by Region (2018-2023)
-
Figure China Biosimilar Insulin Sales Volume Share by Region (2018-2023)
-
Table China Biosimilar Insulin Sales Value by Region (2018-2023)
-
Table China Biosimilar Insulin Sales Value Share by Region (2018-2023)
-
Figure China Biosimilar Insulin Sales Value Share by Region (2018-2023)
-
Table North China Biosimilar Insulin Production Volume by Type (2018-2023)
-
Table North China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Figure North China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Table North China Biosimilar Insulin Sales Volume by Application (2018-2023)
-
Table North China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Figure North China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Table Central China Biosimilar Insulin Production Volume by Type (2018-2023)
-
Table Central China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Figure Central China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Table Central China Biosimilar Insulin Sales Volume by Application (2018-2023)
-
Table Central China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Figure Central China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Table South China Biosimilar Insulin Production Volume by Type (2018-2023)
-
Table South China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Figure South China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Table South China Biosimilar Insulin Sales Volume by Application (2018-2023)
-
Table South China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Figure South China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Table East China Biosimilar Insulin Production Volume by Type (2018-2023)
-
Table East China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Figure East China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Table East China Biosimilar Insulin Sales Volume by Application (2018-2023)
-
Table East China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Figure East China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Table Northeast China Biosimilar Insulin Production Volume by Type (2018-2023)
-
Table Northeast China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Figure Northeast China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Table Northeast China Biosimilar Insulin Sales Volume by Application (2018-2023)
-
Table Northeast China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Table Southwest China Biosimilar Insulin Production Volume by Type (2018-2023)
-
Table Southwest China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Figure Southwest China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Table Southwest China Biosimilar Insulin Sales Volume by Application (2018-2023)
-
Table Southwest China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Table Northwest China Biosimilar Insulin Production Volume by Type (2018-2023)
-
Table Northwest China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Figure Northwest China Biosimilar Insulin Production Volume Share by Type (2018-2023)
-
Table Northwest China Biosimilar Insulin Sales Volume by Application (2018-2023)
-
Table Northwest China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Biosimilar Insulin Sales Volume Share by Application (2018-2023)
-
Table Eli Lilly and Company Company Profile
-
Table Eli Lilly and Company Biosimilar Insulin Revenue, Price and Gross (2018-2023)
-
Table Aspen Company Profile
-
Table Aspen Biosimilar Insulin Revenue, Price and Gross (2018-2023)
-
Table Sanofi Company Profile
-
Table Sanofi Biosimilar Insulin Revenue, Price and Gross (2018-2023)
-
Table BGP Pharma Company Profile
-
Table BGP Pharma Biosimilar Insulin Revenue, Price and Gross (2018-2023)
-
Table Mylan (Viatris) Company Profile
-
Table Mylan (Viatris) Biosimilar Insulin Revenue, Price and Gross (2018-2023)
-
